Cedars-Sinai research published in the New England Journal of Medicine supports FDA approval of drug for thyroid eye disease CEDARS-SINAI MEDICAL CENTER LOS ANGELES (Feb. 9, 2020) — Patients with thyroid eye disease who used the minimally invasive insulin-like growth factor I blocking antibody, teprotumumab, experienced improvement in their symptoms, appearance and quality of life,...
